Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity

Prostate

Volumn 28, Issue 1, 1996, Pages 65-69

  Tjoa, Benjamin ^a   Boynton, Alton ^a   Kenny, Gerald ^a   Ragde, Haakon ^a   Misrock, S Leslie ^b   Murphy, Gerald ^a  

^a NORTHWEST HOSPITAL   (United States)

^b Pennie and Edmonds   (United States)

Author keywords

Dendritic cells; Prostate specific membrane antigen; T cell response

Indexed keywords

HLA A2 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROSTATE TUMOR; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GLUTAMATE CARBOXYPEPTIDASE II; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0030059682     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199601)28:1<65::AID-PROS9>3.0.CO;2-N     Document Type: Article

References (25)

1. Pardoll D: New Strategies for Active Immunotherapy with Genetically Engineered Tumor Cells. Curr Opin Immunol 4:619-623, 1992.
2. Knight SC, Stagg AJ: Antigen-presenting cell types. Curr Opin Immunol 5:374-382, 1993.
3. Thomas R, Davis LS, Lipsky PE: Isolation and characterization of human peripheral blood dendritic cells. J Immunol 150:821-829, 1993.
4. Knight SC, Farrant J, Bryant A, Edwards JA, Burman S, Lever A, Clarke J, Webster ADB: Non-adherent, low-density cells from human peripheral blood contain dendritic cells and monocytes, both with veiled morphology. Immunology 57:595-603, 1985.
5. Tjoa B, Erickson S, Barren R III, Ragde H, Kenny G, Boynton A, Murphy G: In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 27:63-69, 1995.
6. Zinkernagel RM, Doherty PC: Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248:701-702, 1974.
7. Rotzschke O, Falk K, Wallny H, Faath S, Rammense H: Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348:252-254, 1990.
8. Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu NA, Arnott D, Sherman N, Shabanowitz J, Michel H, Bodnar W, Davis TA and Hunt DF: Definition of Specific Peptide motif for four Major HLA-A alleles. J. Immunol. 152:3913-3924, 1994.
9. Falk K, Rotzschke O, Stevanovic S, Jung G and Rammensee HG: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290-296, 1991.
10. Central Data Analysis Committee: "Allele frequencies," Section 6.3. Tsuji K, Aizawa M, Sasazuki T (eds). Tokyo: Oxford University Press, pp 1066-1077.
11. Horroszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 7:927-936, 1987.
12. Murphy GP: Radiostintiscanning of prostate cancer. Cancer 75(suppl):1819-1822, 1995.
13. Murphy GP, Ragde H, Kenny G, Barren R, Erickson S, Tjoa B, Boynton A, Holmes E, Gilbaugh J, and Douglas T: Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res. 15:1473-1480, 1995.
14. Murphy GP, Holmes EH, Boynton AL, Kenny GM, Ostenson RC, Erickson SJ, Barren RJ III: Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunoabsorbent assays in prostatic cancer patients. Prostate 26: 164-168, 1995.
15. Rochon YP, Horoszewicz JS, Boynton AL, Holmes EH, Barren RJ III, Erickson SJ, Murphy GP: Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients. Prostate 25:219-223, 1994.
16. Okada CY, Rechsteiner M: Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles. Cell 29:33-45, 1982.
17. Berhard H, Disis ML, Heimfeld S, Hand S, Gralow JR, Cheever MA: Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 55:1099-1104, 1995.
18. Cassell DJ, Schwartz RH: A quantitative analysis of antigen-presenting cell function: Activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation. J Exp Med 180:1829-1840, 1994.
19. Mehta-Damani A, Markowicz S, Engleman EG: Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol 153:996-1003, 1994.
20. Akdas A, Turkeri L, Alican Y, Simsek F, Akogiu T: Human leukocyte antigen subtype analysis in patients with advanced adenocarcinoma of the prostate. Prostate 24:111-113, 1994.
21. Grabbe S, Beissert S, Schwartz T, Granstein RD: Dendritic cells as initiators of tumor immune response: A possible strategy for immunotherapy? Immunol Today 16:117-121, 1995.
22. Aiba S, Katz SI: The ability of cultured Langerhans cells to process and present protein antigens is MHC dependent. J Immunol 20:2479-2487, 1991.
23. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J: GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhan cells. Nature 360:258-269, 1992.
24. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109-1118, 1994.
25. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83-93, 1994.